Table 2.
Clinical outcomes in eRA cohort after 24 weeks of treatment
| eRA all treatment arms (n = 70) |
MTX + prednisolone (n = 12) |
MTX + anti-TNF (n = 22) |
MTX + CTLA4-Ig (n = 17) |
MTX + anti-IL-6R (n = 19) |
p-value | |
|---|---|---|---|---|---|---|
| CDAI Remission, n (%) | 28 (40) | 2 (16.7) | 8 (36.4) | 10 (59) | 8 (42) | 0.16b |
| CDAIa | 3.8 (0.1–28.3) | 5 (1.6–15.5) | 4.2 (0.2–19.2) | 2.3 (0.1–28.3) | 3.3 (0.1–18.5) | 0.26c |
| TJC 28a | 0.5 (0–19) | 1 (0–11) | 0 (0–4) | 0 (0–19) | 1 (0–15) | 0.26c |
| SJC 28a | 0.0 (0–6) | 0 (0–1) | 0 (0–6) | 0 (0–6) | 0 (0–3) | 0.61c |
| PGAa | 14.5 (0–92) | 19 (2–62) | 14.5 (2–92) | 9 (0–60) | 10 (0–76) | 0.099c |
| EGAa | 6.5 (0–40) | 11 (1–34) | 7.5 (0–40) | 5 (0–24) | 4 (0–22) | 0.33c |
aMedian and range
bDifference between treatment arms, Fisher’s exact test
cDifference between treatment arms, Kruskal-Wallis test
eRA: early Rheumatoid Arthritis; CDAI: Clinical Disease Activity Index; SJC: Swollen Joint Count; TJC: Tender Joint Count; PGA: Patient Global Assessment; EGA: Evaluator Global Assessment